Possible explanation could be that 1) PLK4 inhibitor might inhibiting the activation of several cancer-related signaling pathways (such as Wnt/β-catenin pathway), which further suppress ATC cell viability.16 2) PLK4 inhibitor arrests cell cycle at G2/M phase in ATC cell lines as illustrated in our study, thus leading to a suppression of ATC cell viability. The gene discussed is PLK4; the disease is cancer.